Top Markets
Coin of the day
Eli Lilly and Company Eli Lilly and Company

Eli Lilly and Company

LLY
Helyezés a részvények között #14
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Részvényárfolyam
$1,133.97
Utolsó szinkronizálás: 2026-09-15
Piaci kapitalizáció
$1.068T
Változás (1 nap)
-0.39%
Változás (1 év)
48.29%
Ország
US
Kereskedés Eli Lilly and Company (LLY)

Kategória

Eli Lilly and Company (LLY) nyeresége
Nyereség ekkor: Jun 2026 TTM: $33.59B
Eli Lilly and Company legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $33.59B. 2024 évben a vállalat $12.68B nyereséget ért el, növekedés a 2023 év nyereségéhez, amely $6.55B volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Eli Lilly and Company nyereségtörténete 2000 és 2026 között
Nyereség az év végén
Év Nyereség Változtassa meg
2026 (TTM) $33.59B 30.57%
2025 $25.73B 102.91%
2024 $12.68B 93.46%
2023 $6.55B -3.70%
2022 $6.81B 10.57%
2021 $6.16B -14.86%
2020 $7.23B 37.30%
2019 $5.27B 43.09%
2018 $3.68B 59.67%
2017 $2.30B -31.69%
2016 $3.37B 20.93%
2015 $2.79B -7.01%
2014 $3.00B -49.06%
2013 $5.89B 8.90%
2012 $5.41B 1.10%
2011 $5.35B -18.02%
2010 $6.53B 21.79%
2009 $5.36B -509.74%
2008 $-1.31B -133.73%
2007 $3.88B 13.42%
2006 $3.42B 25.78%
2005 $2.72B -7.63%
2004 $2.94B -9.80%
2003 $3.26B -5.67%
2002 $3.46B -2.66%
2001 $3.55B -7.95%
2000 $3.86B 0.00%
Hasonló cégek vagy versenytársak nyeresége
Vállalat Nyereség Nyereségkülönbség Ország
$25.20B -25.00%
US
$8.70B -74.11%
US
$21.39B -36.33%
CH
$5.95B -82.29%
US
$16.38B -51.25%
CH